Joint Formulary Newsletter
Bedfordshire and Luton Joint Formulary Newsletter
March 2020, Number 3
Incorporates Key Recommendations from The Bedfordshire and Luton Joint Prescribing Committee (JPC) 26th February 2020
The Bedfordshire and Luton Joint Formulary (a combined medicines formulary for use by BCCG, LCCG, Bedford Hospital and the Luton and Dunstable University Hospital) is now ‘live’. It can be accessed here
Unless otherwise stated decisions made apply to all organisations in the Joint Formulary Group.
|FORMULARY TRAFFIC LIGHT STATUS INFORMATION|
|RED||RED - Hospital Only - to be prescribed by a specialist and supplied from secondary care ONLY throughout treatment|
|AMBER||Amber medicines are considered suitable for GP prescribing following specialist initiation|
|GREEN||These medicines are appropriate for initiation in both primary and secondary care. Prescribing is appropriate within licensed or local recommendations|
|SCG||Shared Care - These medicines require specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place, status reverts to RED.|
|BLACK||A decision has been made by either or both the local or national NHS not to routinely commission this preparation for its licensed indications. DO NOT PRESCRIBE|
|The following ADDITIONS to the Joint Formulary were agreed at the JPC Committee Meeting|
No new medicines were added at this meeting
|Hospital Drug and Therapeutic Committee Updates|
Luton and Dunstable Hospital DTC
|CCG Prescribing Committees|
BCCG Prescribing Committee
|Wound Care Formulary Group (Ratified by the JPC)|
No update from the Wound Care Group
|Decisions Made By Joint Formulary Group (Ratified by the JPC)|
Join Formulary updates following publication of NICE Technology Appraisal Guidance.
NICE does not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations will be less than £5 million per year in England (or £9,000 per 100,000 population).
Sotagliflozin with insulin for treating type 1 diabetes, Technology appraisal guidance [TA622] Published date: 12 February 2020, https://www.nice.org.uk/guidance/ta622
Patiromer for treating hyperkalaemia, Technology appraisal guidance [TA623] Published date: 13 February 2020, https://www.nice.org.uk/guidance/ta623
NICE CCG Commissioned Appraisal withdrawn (Monday 10th February 2020):-
NHSE Commissioned- New drugs added
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome, Technology appraisal guidance [TA615] Published date: 18 December 2019, https://www.nice.org.uk/guidance/ta615 – JPC Action – added to Joint Formulary (created and link added) – Hospital Only Prescribing.
Cladribine for treating relapsing–remitting multiple sclerosis, Technology appraisal guidance [TA616] Published date: 19 December 2019
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer.
Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis, Technology appraisal guidance [TA624] Published date: 19 February 2020, https://www.nice.org.uk/guidance/ta624 – recommended – JPC Action – link added to Joint Formulary